Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-week Cycle in Patients With Advanced Malignancies

NCT00741234 is registered in ClinicalTrials.gov with S*BIO as lead sponsor.

NCT NCT00741234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00741234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Study of Oral SB939 When Administered Thrice Weekly (Every Other Day) for 3 Weeks in a 4-week Cycle in Patients With Advanced Malignancies
Lead sponsor
S*BIO
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2007
Completion date
March 31, 2012
Enrollment
85 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignancies, myelodysplastic syndrome, solid tumors